Bob Azelby, Eliem CEO

Ouch: Eliem’s pain drug fails sec­ond PhII tri­al, gets scrapped

In April, Eliem Ther­a­peu­tics’ lead can­di­date, ETX-810, failed a Phase II study for di­a­bet­ic nerve pain, buck­ling the greater Seat­tle-based biotech’s stock by over half. At the time, Eliem CEO and pres­i­dent Bob Azel­by called the re­sults “un­am­bigu­ous” in not pro­vid­ing ben­e­fit for di­a­bet­ic nerve pain (DP­NP).

But Eliem had an­oth­er shot with its pain drug — a sec­ond Phase II tri­al for a form of back pain called lum­bosacral radic­u­lar pain (LSRP), known more com­mon­ly as sci­at­i­ca. This morn­ing Eliem an­nounced that its lead can­di­date had failed in that tri­al too, and that it would be drop­ping the drug al­to­geth­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.